Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $762.00 to $834. ...

Royal Bank of Canada dropped their price objective on Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an “outperform” rating on the stock in a report on Wednesday. Leerink Partners ...

With President Donald Trump expected to deliver a drug pricing order on Monday that Big Pharma and patient groups alike have ...

A comprehensive examination of how financial experts perceive Regeneron Pharmaceuticals is ... Neutral | $759.00|$940.00 | |David Risinger |Leerink Partners |Raises |Outperform | $834.00|$762. ...

Regeneron stock tumbled Tuesday after the biotech giant reported a major revenue miss due to light sales of its eye drug Eylea.

The last upgrade for Regeneron Pharmaceuticals Inc happened on February 5, 2025 when Leerink Partners raised their price target to $834. Leerink Partners previously had a market perform for ...

Deutsche Bank AG boosted its stake in Regeneron Pharmaceuticals by nearly 22% in Q4, now holding 539,269 shares valued at ...

Cantor Fitzgerald gave Regeneron a financial pick-me-up by nudging its 2025 EPS forecast to $26.88 from $26.38. This slight ...

Analysts at Leerink agreed with Sanofi that ... This matches or exceeds the performance of Sanofi and Regeneron’s prized drug Dupixent and Amgen and AstraZenca’s Tezspire—two products that are ...